$12.660
-0.500 (-3.95%)Zum Schluss
KURA-News
KURA-Events
Tech Stocks Rebound, S&P 500 Futures Up 0.35%
Stock futures are pointing to a stronger open as technology stocks rebound from Monday's selloff. The bond market is providing some relief. The 10-year Treasury yield has slipped to around 4.67%, while the 30-year yield is around 5.21%, after the long-end of the curve came under significant pressure last week. The market is also looking ahead to Wednesday's PCE inflation report. Economists expect monthly headline PCE to rise 0.1% after falling 0.1% in June.The U.S. has begun imposing tougher sanctions on Iran and is threatening countries that continue trading with Tehran, but crude prices have eased. Brent is around $88 a barrel and WTI around $82, giving stocks some relief from the inflation concerns that pushed oil higher last week.In pre-market trading, S&P 500 futures rose 0.35%, Nasdaq futures rose 0.75% and Dow futures rose 0.39%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Kura Oncologyup 9% after disclosing that its CEO Troy Wilson bought 100K shares of common stock on in a total transaction size of $1.11MNavitas Semiconductorup 5% after signing a definitive agreement to acquire Claros in deal valued at up to $232.8MUnited Airlinesup 3% after announcing the largest international network expansion in company history with 10 new international cities and three new routes across Europe and AsiaAMDup 2% after Raymond James upgraded the stock to Strong Buy from Outperform with a price target of $641, up from $565Boeingup 1% after being awarded a $131.23B ceiling, indefinite-delivery/indefinite-quantity contract for the F-15 Eagle CrestUP AFTER EARNINGS -Scotiabankup 2%DOWN AFTER EARNINGS -Dick's Sportingdown 15%Vipshopdown 3%Citi Trendsdown 1%
Tech Weakness Weighs on S&P 500 and Nasdaq
Fragile sentiment in the tech space weighed on broader indices as S&P 500 and Nasdaq Composite begin the final full week of August with a loss. Semiconductors and memory stocks were the hardest hit on Monday as investors digest capital return announcement from Samsunglate last week, fret about press reports that Nvidiahas flagged price hikes, and also position for Nvidia earnings, PCE inflation, and Fed Chair Wash speech at Jackson Hole this week. Technology and Industrials were the worst-performing sectors in the benchmark index. In turn, Consumer Defensive names outperformed, with traders rotating into discount retail giants that fell out of favor last week on disappointing results - Walmartwas up 2.7% and Costcowas up 2.5%. Credit Services was also strong as Visaand Mastercardboth gained over 3% on Monday.In the opening hour of the evening session index futures are a little changed - S&P e-minis and Nasdaq 100 contracts are just above 7,670 and 29,100 respectively. In commodities, WTI Crude Oil continues to trade in a narrow band in the mid-$80s. Precious metals however have sustained their furious rebound - Gold prices were at 3-month highs near $4,740 and Silver is targeting a breach above $70 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Kura Oncologyup 6.3% after insider buyHerc Holdingsup 1.5% after insider buyVistraup 0.9% after insider buyBoeingup 0.4% after $131B USAF contractDOWN AFTER EARNINGS -Gorilla Technologydown 9.0%PicS N.V.down 2.7%ALSO LOWER -Daqo New Energydown 1.9% after Goldman Sachs downgradeTrade Deskdown 1.0% after mixed shelf offering
S&P 500 Index Retreats for Second Consecutive Session
S&P 500 index retreated for the second consecutive trading session on Monday and has now erased gains made over the prior two trading sessions last week. Consumer sectors, both staples and cyclicals, were among the worst-performing areas of the benchmark. Energy once again helped to prop up the S&P 500 as its best-performing index, thanks to the geopolitical uncertainty in the Strait of Hormuz. In technology, sentiment was split down the middle: pro-AI capex stocks held up, with Micron, Sandisk, Western Digital, and Applied Materialstrading notably higher. Stocks in Software and IT Services largely offset that advance, with names like Microsoftanddown 3.0% and 2.3% respectively.On Tuesday, traders will see earnings from a premium home builder - Toll Brothers- and a home improvement giant in Home Depot (HD), further gauging the impact of stubbornly high interest rates on the housing sector.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Flexsteel Industriesup 10.0%Duos Technologiesup 7.5%Yalla Groupup 1.4%.ALSO HIGHER -Amylyx Pharmaceuticalsup 13.2% after announcing expected results for Avexitide tomorrowKura Oncologyup 8.2% after insider buyButterfly Networkup 4.1% after insider buyDOWN AFTER EARNINGS -Fabrinetdown 6.5%ALSO LOWER -Andersen Groupdown 4.6% after equity offering
Kura Oncology Reports Q2 Revenue of $20.87M, Exceeding Expectations
Reports Q2 revenue $20.87M, consensus $20.18M. "In only its second full quarter of launch, KOMZIFTI established early leadership in relapsed or refractory NPM1-mutant AML, achieving a majority share of new patient starts in the menin inhibitor class," said Troy Wilson, President and Chief Executive Officer of Kura Oncology. "Increasing physician preference for KOMZIFTI, combined with outstanding commercial execution and encouraging frontline data, establish a strong foundation for ziftomenib as a potential market leader throughout the AML treatment continuum. In parallel, darlifarnib is emerging as a differentiated precision combination platform across multiple targeted therapies in major solid tumor indications. Together, these programs position Kura to build long-term value while advancing innovative therapies for patients with significant unmet need."
Kura Oncology Publishes Ziftomenib Research Findings
Kura Oncology announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and preclinical development of ziftomenib, a potent and selective menin inhibitor approved by the FDA in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The publication describes the scientific foundation underlying ziftomenib's development, including its differentiated binding profile, potent and selective inhibition of the menin-KMT2A interaction, activity across multiple genetically defined leukemia models, and activity against certain treatment-emergent MEN1 mutations associated with resistance to other menin inhibitors. Across KMT2A-rearranged, NPM1-mutated and NUP98-rearranged leukemia models, ziftomenib demonstrated potent on-target activity, including suppression of key KMT2A-regulated genes such as MEIS1 and HOXA9, induction of differentiation, and reduced leukemia cell viability. Ziftomenib also was shown to induce leukemia regression and extended survival in multiple xenograft and patient-derived xenograft models.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.